Datopotamab Deruxtecan, often abbreviated as DATO, represents an important advancement in targeted cancer care. This innovative antibody-drug conjugate joins the monoclonal antibody specifically targeting HER2 positive https://bookmarklinking.com/story10910016/dato-deruxtecan-an-promising-adc-compound